Le Lézard

PADCEVtm + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Pfizer Inc. and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for ...
PharmiWeb

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...

KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclit…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the final analysis of ...
Women's Health

Your One-Stop Shop For All The Women's Health Training Guides

Looking for a detailed training program that can help you reach your goals? Looking for a detailed training program that can help you reach your goals? Women's Health guides have helped women all over ...